Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04756232 · ClinicalTrials.gov registry record · Early Phase 1
Cholinergic Mechanisms of Attention in Aging
A Early Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
NCT04756232 is a Early Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 19 participants.
The verdict
NCT04756232, a Early Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with SCD compared to those without SCD.
Interventions
- DRUG Mecamylamine Challenge
- OTHER Placebo Comparator Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2025-05-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04756232
The ClinicalTrials.gov registry entry for NCT04756232 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mecamylamine Challenge is the first listed.
NCT04756232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04756232 about?
NCT04756232 is a clinical study titled "Cholinergic Mechanisms of Attention in Aging". This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic funct...
What is the current status of trial NCT04756232?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2022-04-21. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT04756232?
The interventions under investigation include: Mecamylamine Challenge (DRUG), Placebo Comparator Challenge (OTHER).
Who is sponsoring clinical trial NCT04756232?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.